SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000909661-04-000087
Filing Date
2004-11-08
Accepted
2004-11-08 17:27:44
Documents
1
Group Members
CHARLES E. ELLWEINCHUN R. DINGDAVID I. COHENDEREK C. SCHRIERFARALLON CAPITAL INSTITUTIONAL PARTNERS II, L.P.FARALLON CAPITAL INSTITUTIONAL PARTNERS III, L.P.FARALLON CAPITAL INSTITUTIONAL PARTNERS, L.P.FARALLON CAPITAL PARTNERS, L.P.FARALLON PARTNERS, L.L

Document Format Files

Seq Description Document Type Size
1 ligand13g.txt SC 13G 92021
  Complete submission text file 0000909661-04-000087.txt   94839
Mailing Address 10275 SCIENCE CENTER DRIVE SAN DIEGO CA 92121-1117
Business Address 10275 SCIENCE CENTER DRIVE SAN DIEGO CA 92121-1117 8585507500
LIGAND PHARMACEUTICALS INC (Subject) CIK: 0000886163 (see all company filings)

IRS No.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-43329 | Film No.: 041126809
SIC: 2834 Pharmaceutical Preparations

Mailing Address ONE MARITIME PLAZA SAN FRANCISCO CA 94111
Business Address ONE MARITIME PLAZA STE 11325 SAN FRANCISCO CA 94111 4154212132
FARALLON CAPITAL MANAGEMENT LLC (Filed by) CIK: 0000909661 (see all company filings)

IRS No.: 943240279